The Latest Trading Price of Krebs Biochemicals & Industries Ltd is ₹ 58.92 as of 04 May 15:30
. The P/E Ratio of Krebs Biochemicals & Industries Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of OneSource Specialty Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Krebs Biochemicals & Industries Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of OneSource Specialty Pharma Ltd changed from ₹ 20003 crore on March 2025 to ₹ 20003 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of OneSource Specialty Pharma Ltd for the Dec '25 is ₹ 294.97 crore as compare to the Sep '25 revenue of ₹ 378.8 crore. This represent the decline of -22.13% The ebitda of Krebs Biochemicals & Industries Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of OneSource Specialty Pharma Ltd for the Dec '25 is ₹ 14.86 crore as compare to the Sep '25 ebitda of ₹ 109.53 crore. This represent the decline of -86.43% The net profit of Krebs Biochemicals & Industries Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0%
The net profit of OneSource Specialty Pharma Ltd changed from ₹ -5.55 crore to ₹ -88.7 crore over 7 quarters. This represents a CAGR of 387.29%
The Dividend Payout of Krebs Biochemicals & Industries Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of OneSource Specialty Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Krebs Biochemicals & Industries Ltd
Krebs Biochemicals & Industries Ltd (Formerly Krebs Biochemicals Ltd), promoted by R T Ravi in 1991 is engaged in the manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same.
Krebs develops commercially viable biotech processes for application in medicine, agriculture and industry.
Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies.
KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994.
During 2001-02, the company launched Vitamin C(I P Grade) through Fermentation Process.
About OneSource Specialty Pharma Ltd
Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore.
The Company name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies.
The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021,.
Subsequently, the name was changed to its present Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.
FAQs for the comparison of Krebs Biochemicals & Industries Ltd and OneSource Specialty Pharma Ltd
Which company has a larger market capitalization, Krebs Biochemicals & Industries Ltd or OneSource Specialty Pharma Ltd?
Market cap of Krebs Biochemicals & Industries Ltd is 127 Cr while Market cap of OneSource Specialty Pharma Ltd is 20,132 Cr
What are the key factors driving the stock performance of Krebs Biochemicals & Industries Ltd and OneSource Specialty Pharma Ltd?
The stock performance of Krebs Biochemicals & Industries Ltd and OneSource Specialty Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Krebs Biochemicals & Industries Ltd and OneSource Specialty Pharma Ltd?
As of May 5, 2026, the Krebs Biochemicals & Industries Ltd stock price is INR ₹58.92. On the other hand, OneSource Specialty Pharma Ltd stock price is INR ₹1756.15.
How do dividend payouts of Krebs Biochemicals & Industries Ltd and OneSource Specialty Pharma Ltd compare?
To compare the dividend payouts of Krebs Biochemicals & Industries Ltd and OneSource Specialty Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.